Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT01388036
Other study ID # 397-27.05.05
Secondary ID
Status Recruiting
Phase N/A
First received July 3, 2011
Last updated July 5, 2011
Start date July 2011

Study information

Verified date July 2011
Source Hadassah Medical Organization
Contact Mordechai Muszkat, MD
Phone 972-2-6777111
Email muszkatm@hadassah.org.il
Is FDA regulated No
Health authority Israel: Ministry of Health
Study type Interventional

Clinical Trial Summary

Beta 1 Adrenergic antagonists (beta blockers) have major role in the treatment of CHF, IHD and hypertension. However, there is large interindividual variability in the response to beta blockers.

The hypothesis underlying this study is that genetic differences between individuals will determine the individual response to esmolol, a betablocker that is administered intravenously. Esmolol will be administered intravenously to healthy volunteers, and the effects on heart rate and blood pressure will be monitored. In addition, we will measure plasma renin activity and plasma levels of norepinephrine.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date
Est. primary completion date May 2015
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria:

- healthy male and female

- able to understand and sign informed consent

Exclusion Criteria:

- consumption of any medication

- bradycardia <50 BPM

- hypersensitivity to beta blockers

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science


Related Conditions & MeSH terms

  • Decrease in Heart Rate Below Baseline Value

Intervention

Drug:
esmolol
consecutive infusions of esmolol and normal saline (placebo)

Locations

Country Name City State
Israel Hadassah Hebrew University Medical Center Jerusalem

Sponsors (1)

Lead Sponsor Collaborator
Hadassah Medical Organization

Country where clinical trial is conducted

Israel, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in heart rate during exercise continous measurement of heart rate 3 hours Yes
Secondary change in systolic blood pressure during exercise measurement of systolic blood pressure every 5 minutes 3 hours Yes